INCLUSION CRITERIA
At least 1 sign of volume overload (oedema, ascitis, pleural effusion)
≥ 1 month maintenance dose of loop diuretics (≥ 1 mg bumetanide, ≥ 40 mg furosemide, ≥ 20 mg torsemide)
BNP > 250 pg/ml or NT-proBNP > 1000 pg/ml
Assessed LVEF by any imaging techniques within 12 months of inclusion
EXCLUSION CRITERIA
At admission / screening
– Treatment with acetazolamide and/or IV loop diuretics > 2 mg prior to randomization
– Estimated glomerular filtration rate <20 mL/min/1.73m²
– Systolic blood pressure <90mm Hg or MAP <65mm Hg
– Pregnant/breastfeeding subjects
– Diagnosis of acute coronary syndrome
– Current or expected use of “forbidden” agents (e.g. SGLT-2 inhibitors, IV inotropes, vasopressors or
nitroprusside)At any time before study inclusion
– History of congenital heart disease or cardiac transplantation and/or ventricular assist device
– Use of renal replacement therapy or ultrafiltrationUse of any non-protocol defined diuretic agent should be stopped upon study inclusion